SEMINARS IN CANCER BIOLOGY
Scope & Guideline
Fostering innovation in cancer understanding.
Introduction
Aims and Scopes
- Molecular Mechanisms of Cancer:
Research articles often explore the underlying molecular pathways involved in cancer development and progression, including signaling pathways, gene expression regulation, and metabolic alterations. - Therapeutic Strategies and Innovations:
The journal emphasizes the exploration of new therapeutic approaches, including targeted therapies, immunotherapies, and the use of nanomedicine in cancer treatment. - Tumor Microenvironment and Metastasis:
A significant focus is placed on understanding the interactions between tumor cells and their microenvironment, which contribute to metastasis and therapeutic resistance. - Role of Extracellular Vesicles:
Extracellular vesicles are frequently studied for their role in cancer signaling, communication, and potential as biomarkers for diagnosis and therapy. - Emerging Technologies and Techniques:
The journal highlights advancements in technologies such as artificial intelligence, machine learning, and computational biology that enhance cancer research and treatment. - Cancer and Aging:
Research on the interplay between aging and cancer is a consistent theme, exploring how age-related factors influence cancer biology and treatment outcomes.
Trending and Emerging
- Artificial Intelligence in Oncology:
The use of artificial intelligence for diagnostics, treatment prediction, and personalized medicine is rapidly gaining traction, with numerous articles exploring its applications in oncology. - Immunotherapy and Immune Checkpoint Inhibitors:
Research on immunotherapy, particularly immune checkpoint inhibitors, is becoming increasingly prominent as a key strategy in cancer treatment, with a focus on enhancing efficacy and overcoming resistance. - Extracellular Vesicles as Therapeutic Agents:
There is a growing trend in studying extracellular vesicles not only as biomarkers but also as potential therapeutic agents and delivery systems for cancer therapies. - Cancer Metabolism and Nutritional Interventions:
Emerging research is focusing on the metabolic characteristics of cancer cells and the role of diet and nutrition in cancer prevention and therapy. - Microbiome and Cancer Interactions:
The relationship between the microbiome and cancer is gaining attention, with studies investigating how gut microbiota influences cancer progression and treatment response. - Targeted and Combination Therapies:
A trend towards combination therapies that target multiple pathways simultaneously is emerging, reflecting a more integrated approach to cancer treatment.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decline in articles focusing solely on traditional chemotherapy methods, as the field shifts towards personalized medicine and targeted therapies that offer improved efficacy and reduced side effects. - Basic Cancer Biology without Translational Focus:
Papers that discuss basic cancer biology without a translational perspective are becoming less common, as the journal emphasizes studies that directly link laboratory findings to clinical applications. - Single-Pathway Inhibition Strategies:
Research dedicated to targeting single molecular pathways is decreasing, as more emphasis is placed on multi-targeted approaches that consider the complexity of cancer biology. - Invasive Surgical Techniques:
There has been a reduction in discussions around invasive surgical techniques, as the field is increasingly exploring less invasive options, such as precision medicine and minimally invasive therapies.
Similar Journals
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Fostering collaboration for groundbreaking cancer discoveries.The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.
Annual Review of Cancer Biology
Exploring the Complexities of Cancer ScienceAnnual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.
Oncologie
Exploring innovative solutions in oncology.Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.
NATURE REVIEWS CANCER
Illuminating the Path to Cancer UnderstandingNATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.
NEOPLASMA
Pioneering Insights in Neoplastic DiseasesNEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.
EXPERIMENTAL CELL RESEARCH
Unveiling Innovations in Experimental ResearchEXPERIMENTAL CELL RESEARCH is a highly respected journal published by Elsevier Inc, specializing in the dynamic and ever-evolving field of Cell Biology. With an impact factor positioned in the Q2 quartile for 2023, it ranks at the 124th position out of 285 in the Scopus Ranks, indicating a solid reputation among peers in the domains of biochemistry, genetics, and molecular biology. Since its inception in 1950, the journal has contributed significantly to the dissemination of groundbreaking research, providing a platform for studies that explore the nuances of cellular mechanisms, processes, and experimental methodologies. Although the journal currently does not offer open access, its commitment to high-quality, peer-reviewed research continues to attract submissions from leading scientists and scholars across the globe. Researchers, professionals, and students alike will find this journal an invaluable resource for keeping abreast of current developments and innovative breakthroughs in cellular science.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Synthesis of Cutting-Edge Cancer DiscoveriesBIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.
Cancer Cell International
Unveiling Innovations in Cancer BiologyCancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.
Trends in Cancer
Transforming Cancer Research Through Scholarly ExcellenceTrends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.
Molecular & Cellular Oncology
Exploring the cellular mechanisms of oncogenesis.Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.